| | Presentation | Media | Date |
| AlzeCure Pharma presentation at Redeye Neurology Day October 15
| |
|
October 15, 2025
|
| CEO Martin Jönsson presents AlzeCure Pharma, the project pipeline and the science behind it.
|
|
|
September 26, 2025
|
| Poster from NeuPSIG 2025 - Analgesic and anti-inflammatory effects of ACD137, a potent and selective negative allosteric modulator of TrkA.
|
|
|
September 8, 2025
|
| Poster from NeuPSIG 2025 - The TRPV1 antagonist ACD440 Gel as a tool in pain precision medicine, results of a post hoc analysis
|
| |
September 4, 2025
|
| Presentation about the Orphan Drug Market and its opportunities and development by Dimitrina Dimitrova, Karolinska
|
|
|
August 27, 2025
|
| Presentation about Painless ACD440 and its orphan designation and opportunity within erytheromelalgia by AlzeCure’s CMO Märta Segerdahl
|
|
|
August 27, 2025
|
| Seminar on Painless ACD440 against erytheromelalgia and the opportunities within the orphan drug market and for erytheromelalgia. With presentations by AlzeCure’s CMO Märta Segerdahl, Dimitrina Dimitrova, consultant, and AlzeCure’sCEO Martin Jönsson
|
|
|
August 27, 2025
|
| AlzeCure Pharma's CEO, Martin Jönsson at BioStock - Progress & the Right issue. 8 July 2025 (Swedish)
| |
|
July 8, 2025
|
| AlzeCure Pharma's CEO, Martin Jönsson at BioStock – A good momentum, July 8, 2025 (Swedish)
| |
|
July 8, 2025
|
| AlzeCure Pharma's CEO, Martin Jönsson at Aktiespararna, July 8, 2025 (Swedish)
| |
|
July 8, 2025
|
| AlzeCure´s CEO, Martin Jönsson at BioStock, July 2, 2025
| |
|
July 2, 2025
|
| AlzeCure Pharma´s CEO, Martin Jönsson & CSO, Johan Sandin at Redeye (Swedish)
| |
|
June 23, 2025
|
| AlzeCure Pharma´s CEO, Martin Jönsson at Redeye (Swedish)
| |
|
June 13, 2025
|
| AlzeCure Pharma´s CEO, Martin Jönsson present at Redeye Investor Forum
|
|
|
June 11, 2025
|
| AlzeCure Pharma´s CEO, Martin Jönsson presents at Aktiedagarna (Swedish)
| |
|
June 10, 2025
|
| Nordic Asia Life-science Summit
|
| |
May 28, 2025
|
| AlzeCure´s CEO, Martin Jönsson at Redeye Theme: Alzheimer & Parkinsons
|
|
|
April 8, 2025
|
| CEO, Martin Jönsson and CSO, Johan Sandin at Redeye - Indicates opportunities in obesity for NeuroRestore ACD856, (Swedish)
| |
|
April 7, 2025
|
| Further investigation on the immunomodulatory and anti-inflammatory effects of NeuroRestore ACD856, a Trk-PAM in clinical development for the treatment of Alzheimer’s disease
|
| |
April 7, 2025
|
| Christina Parrado-Fernández summarizes the abstract with preclinical data on NeuroRestore ACD856 demonstrating its anti-inflammatory and immunomodulatory effects, presented at the international conference AD/PD 2025, in Vienna on April 1-5.
|
|
|
April 1, 2025
|
| CEO Martin Jönsson at Finwire - Report for the fourth quarter (Swedish)
| |
|
February 27, 2025
|
| CEO Martin Jönsson at Finwire – The company's latest advances in Alzheimer's research (Swedish)
| |
|
February 27, 2025
|
| CEO, Martin Jönsson at Redeye - About Q4 reports etc. (Swedish)
| |
|
February 27, 2025
|
| CEO Martin Jönsson at Redeye - "Shows potentially revolutionary findings" (Swedish)
| |
|
February 25, 2025
|
| Summary of article that was publish in The Journal of Pharmacology and Experimental Therapeutics
|
|
|
February 24, 2025
|
| SITDOWN at Finwire - Receives EU grant from EIC
| |
|
February 21, 2025
|
| AlzeCure at Redeye – AlzeCure receives EU grant for Phase 2 clinical trial of NeuroRestore ACD856 for Alzheimer's disease (Swedish)
| |
|
February 18, 2025
|
